Press releases and financial reports
In the CombiGenes pressroom you will find press releases, newsletters, and the latest reports. High resolution images as well as logos are available for use in articles and in newsstands.
Copyright applies to all footage.
Regulatory news 2020 2021 2020 2019 2018 2017 2016 2015 The nominating committee has been constituted in accordance with the resolution adopted by the annual general meeting (“AGM”) 2020 The AGM 2020 resolved that a nominating committee should be appointed...read more
Regulatory news 2020 2021 2020 2019 2018 2017 2016 2015 Today, the exercise period for subscription of shares in CombiGene AB (publ) ("CombiGene" or the “Company”) begins on the basis of warrants of series TO4 and TO5. Each warrant of series TO4 and TO5...read more
Regulatory news 2020 2021 2020 2019 2018 2017 2016 2015 Interim Report January – September 2020 for CombiGene AB (publ)för CombiGene AB (publ) About CombiGene CombiGene’s vision is to provide patients affected by severe life-altering diseases with the...read more
Regulatory news 2020 2021 2020 2019 2018 2017 2016 2015 CombiGene’s lipodystrophy project CGT2 is in an exciting phase where different drug candidates are evaluated with the goal of selecting the final candidate for further preclinical studies in 2021. A...read more
Regulatory news 2020 2021 2020 2019 2018 2017 2016 2015 Analysguiden has today updated its analysis of CombiGene. You can find the result here: https://www.aktiespararna.se/analysguiden/article/796368 2021 » News » Regulatory news » Financial reports...read more
Find it easy
"This is an English translation of the Swedish website; if there is any inconsistency or ambiguity between the English version and the Swedish version, the Swedish version shall prevail. For a complete list of regulatory-related press releases, please refer to the Swedish website"
CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations. The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 firstname.lastname@example.org.